Kannan Rangaramanujam
Arnall Patz Distiniguished Professor of Ophthalmology/Co-director, Center for Nanomedicine
Wilmer Eye Institute, Johns Hopkins Medicine
Dr. Kannan Rangaramanujam is the Arnall Patz Distinguished Professor of ophthalmology and co-director of Center for Nanomedicine at Johns Hopkins Medicine. His research interests are in the field of translational nanomedicine centered on unique ‘cell-targeted dendrimer nanomedicines’. His team has developed approaches to target and manipulate injured glia/macrophages specifically, without a need for ligands, from systemic administration. Targeted therapies for neuroinflammation and angiogenesis are being developed with this approach, with significant implications for addressing unmet needs in many CNS, systemic and ocular disorders, and cancer (e.g., pediatric brain disorders, age-related macular degeneration, diabetic retinopathy, cerebral palsy, immunotherapy, neuroimaging). He is an author of >110 patents (issued and pending, licensed), >140 peer-reviewed publications, and is supported by significant NIH and federal funding. He is the co-founder of Ashvattha Therapeutics Inc., a clinical-stage spinoff that is translating his team’s inventions to the clinic for wet AMD, CNS disorders and neuroimaging.